Atropinic (Anticholinergic) Burden in Parkinson's Disease

被引：18

作者：

De Germay, Sibylle ^{[1
,2
,3
,4
]}

Montastruc, Jean-Louis ^{[1
,2
,3
,4
,5
,6
,7
]}

Rousseau, Vanessa ^{[1
,2
,3
,4
,5
,6
]}

Chebane, Leila ^{[1
,2
,3
]}

Bondon-Guitton, Emmanuelle ^{[1
,2
,3
,4
]}

Moulis, Florence ^{[1
,2
,3
]}

Durrieu, Genevieve ^{[1
,2
,3
]}

Bagheri, Haleh ^{[1
,2
,3
,4
,7
]}

Rascol, Olivier ^{[1
,2
,5
,6
,7
,8
]}

Pariente, Antoine ^{[9
,10
,11
]}

Begaud, Bernard ^{[9
,10
,11
]}

Montastruc, Francois ^{[1
,2
,3
,4
,5
,6
,7
,9
,10
]}

机构：

[1] Ctr Hosp Univ, Serv Pharmacol Med & Clin, Toulouse, France

[2] Fac Med Toulouse, Toulouse, France

[3] Ctr Hosp Univ Toulouse, Ctr Midi Pyrenees PharmacoVigilance Pharmacoepide, Toulouse, France

[4] Univ Toulouse, Fac Med, INSERM UMR 1027, Toulouse, France

[5] Univ Toulouse, CIC INSERM 1436, Toulouse, France

[6] Ctr Hosp Univ Toulouse, Toulouse, France

[7] Univ & Ctr Hosp Univ, NeuroToul Ctr Excellence Neurodegenerat, Amiens, France

[8] Univ Toulouse, INSERM UMR 825, Toulouse, France

[9] Univ Bordeaux, Dept Pharmacol, Bordeaux, France

[10] Ctr Hosp Univ Bordeaux, Bordeaux, France

[11] Univ Bordeaux, Pharmacoepidemiol, INSERM, U657, Bordeaux, France

来源：

MOVEMENT DISORDERS | 2016年 / 31卷 / 05期

关键词：

atropinic drugs; anticholinergic drugs; atropinic burden; anticholinergic burden; Parkinson's disease; UPDATE TREATMENTS; SYMPTOMS; DRUGS; PHARMACOVIGILANCE; ASSOCIATIONS; MEDICATION; SCALES; FORMS; RISK;

D O I：

10.1002/mds.26595

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Use of atropinic drugs remains controversial in Parkinson's disease (PD) because there is insufficient evidence about their efficacy and they can induce serious adverse drug reactions. Atropinic risk scales were developed to help to identify atropinic drugs in prescription forms and to evaluate their burden in clinical practice. In the present review, we discuss the few studies investigating atropinic burden in PD and present the results of our study indicating that atropinic drugs are still widely prescribed in PD (almost 3 of 5 prescriptions) with a clinically significant atropinic burden in around 1 of 6 PD patients. Drugs mainly responsible for high values of atropinic burden were those used for nonmotor symptoms. Clinically significant atropinic burdens were mainly induced by associations of several low-risk drugs. Physicians must be aware that in addition to classical atropinic antiparkinsonian drugs, many others (psychotropics) can contribute to increased atropinic burden in PD patients. (c) 2016 International Parkinson and Movement Disorder Society

引用

页码：632 / 636

页数：5

共 25 条

[1]

Brown JH., 2011, GOODMAN GILMANS PHAR, P219

[2] The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the 'Oldest Old': A Systematic Review of the Literature [J].